TimePie’s 7th longevity forum will bring together researchers, clinicians and investors as China expands its role in healthy aging innovation.
China’s longevity sector is quietly growing up, and its next major reality check happens this September in Shanghai. The 7th TimePie Longevity Forum will bring together some 2,000 researchers, clinicians, tech developers and investors. But unlike the speculative gatherings that characterized the industry’s infancy, the brief for this two-day event (12–13 September) is stubbornly practical: implementation.
The agenda covers considerable ground – spanning fundamental geroscience, clinical models, emerging tech and investment flows – and features 40–50 international speakers. Yet the undercurrent this year is less about marveling at the biology of aging, and far more about the unglamorous but necessary mechanics of how to responsibly plug that science into existing healthcare systems.
Longevity.Technology: If longevity medicine is to become a genuine healthcare discipline rather than a collection of promising but disconnected innovations, it needs ecosystems capable of bringing together science, clinical practice, capital and patients at meaningful scale. China is increasingly positioning itself as one of those ecosystems. While much of the longevity industry’s narrative has historically been shaped by North America and Europe, demographic realities are creating powerful momentum elsewhere; with more than 323 million people over the age of 60, healthy aging is not simply a scientific ambition in China, but an economic and societal imperative. Against this backdrop, the continued growth of the TimePie Longevity Forum feels noteworthy. Now in its seventh year, the event has evolved alongside China’s own longevity sector, reflecting both the maturation of the market and growing international interest in its development. There is perhaps a smidge of irony that a field dedicated to extending healthy lifespan is itself beginning to show signs of maturity; however, as longevity medicine moves from theory toward implementation, the ability to convene researchers, clinicians, investors and operators around shared challenges could well prove every bit as important as the next breakthrough emerging from the laboratory.
The implementation era
For years, longevity in China has been discussed largely in terms of potential – a vast, aging population, rising health awareness and a growing appetite for prevention. While potential is useful, implementation is notoriously harder; increasingly, however, that is where the market is moving. The shift is becoming visible across the healthcare landscape: longevity clinics are emerging within major public hospital systems, private medical groups are refining personalized prevention programs and international players are navigating routes into the country via special-access pathways and flagship partnerships.
What is taking shape is less a new wellness category than a gradual attempt to build a healthcare discipline. Diagnostics, biomarker tracking and targeted interventions are moving closer to established clinical frameworks, raising questions that are as practical as they are scientific. Which measures really move the needle? Which interventions justify their cost? And perhaps most importantly, what does good evidence actually look like in a field that remains young by medical standards?
An awkward middle ground
Longevity has never suffered from a shortage of ideas, but translating those ideas into something a physician can prescribe and a patient can actually receive has proved rather harder. Much of the discussion in Shanghai will orbit that problem – the stubborn, expensive and frequently unglamorous business of turning biological insight into clinical reality.
The scientific program includes researchers such as Raul Mostoslavsky and Barry Halliwell, who are expected to discuss developments across stem cell biology, tissue regeneration, epigenetic regulation and metabolic dysfunction. These areas sit close to the heart of contemporary geroscience, yet the distance between a promising mechanism and a meaningful clinical intervention remains considerable.
None of this is especially headline-friendly. Biomarker validation rarely generates the excitement of a putative age-reversal therapy. Questions around clinical pathways, patient selection and standards of evidence can appear almost pedestrian by comparison, but these are precisely the issues that determine whether longevity medicine becomes a durable clinical discipline or remains an intriguing collection of possibilities.
A dynamic line-up
The forum’s speaker roster reflects the unusually broad church that longevity has become. Alongside established researchers, figures including gerontologist Aubrey de Grey and biohacker Dave Pascoe will offer perspectives that originate well beyond conventional healthcare settings.
It is an eclectic mix, but then longevity has always been a slightly unruly field. Academic geroscientists, biotech entrepreneurs, physicians, self-trackers and investors do not naturally occupy the same professional orbit, but strange bedfellows can make for fascinating conversation – and insight. New ideas often emerge where disciplines overlap, and robust argument can foster creation.
An accompanying exhibition will feature around 30 international pioneers showcasing their products and models across areas including diagnostics, regenerative medicine and clinical longevity services. For attendees, it offers an opportunity to move beyond abstract discussion and examine how longevity technologies are beginning to appear in real products, real clinics and real business models.
Writing the playbook
Among the forum’s outputs will be an updated longevity clinic white paper developed with academic and industry partners, including Fudan University. On paper, it might sound like a modest undertaking, but the question of what constitutes a longevity clinic is becoming increasingly relevant. Around the world, providers are adopting the label with remarkable enthusiasm, while consensus around standards, governance and clinical scope remains a work in progress.
The report is expected to examine how aging-related interventions can be integrated into healthcare systems while maintaining scientific rigor and regulatory oversight. Particular attention will be paid to the infrastructure that sits behind longevity services – the biological materials, assessment platforms and operational frameworks that rarely attract headlines but often determine whether a model succeeds.
Closing the loop
The event also maintains a direct connection to scientific research through the TimePie Longevity Research Grant, which channels net proceeds from the forum into early-stage longevity projects.
The initiative has previously supported work spanning senescent cell clearance, ovarian aging and AI-enabled drug discovery. For 2026, grants will once again be awarded internationally.
The arrangement is notable because it closes a loop that many emerging sectors struggle to maintain. Conferences generate conversations; successful companies generate revenue; science generates future opportunities. Keeping those elements connected is not always straightforward. In longevity, where commercial enthusiasm can occasionally run ahead of the evidence base, mechanisms that return resources to research may become increasingly valuable.
Beyond the conference hall
Longevity science advances in many places – laboratories, clinics, startups, hospital corridors and the humble spreadsheet. Progress is rarely linear and consensus remains elusive – yet every emerging discipline eventually reaches a point where it needs shared forums, common language and a degree of collective self-examination.
That, perhaps, is what gatherings such as TimePie’s forum increasingly represent. Not a celebration of longevity’s arrival, but an opportunity to ask harder questions about where the field is going, how it intends to get there and who will help shape the journey.
Join TimePie in Shanghai to connect with leading experts and be part of a global dialogue that is helping to advance the future of longevity – plus, use the code “LONGEVITY” for 20% off at the checkout!
The 7th TimePie Longevity Forum runs 12–13 September, in Shanghai, China.
